Sunshine Biopharma, Inc. (SBFM)

Market Cap	5.56M
Revenue (ttm)	32.96M
Net Income (ttm)	-4.23M
Shares Out	2.00M
EPS (ttm)	-26.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	109,748
Open	2.750
Previous Close	2.800
Day's Range	2.700 - 2.900
52-Week Range	2.106 - 608.000
Beta	-0.95
Analysts	Strong Buy
Price Target	15.00 (+439.57%)
Earnings Date	Nov 5, 2024

About SBFM

Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver c...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2006
• Employees: 44
• Stock Exchange: NASDAQ
• Ticker Symbol: SBFM
• Website: https://sunshinebiopharma.com

Financial Performance

In 2023, Sunshine Biopharma's revenue was $24.09 million, an increase of 454.42% compared to the previous year's $4.35 million. Losses were -$4.51 million, -83.15% less than in 2022.

Analyst Forecast

According to one analyst, the rating for SBFM stock is "Strong Buy" and the 12-month stock price forecast is $15.0.

Price Target

$15.0

(439.57% upside)

Analyst Consensus: Strong Buy